Stocks
ImmunityBio, Inc.IBRX
NASDAQHealthcareBiotechnology$8.39+7.29%
Focused on developing immunotherapy and cell therapy products for cancer and infectious diseases, ImmunityBio is a clinical-stage biopharmaceutical company. Investors track its progress due to its pipeline targeting high-need oncology indications and partnerships with major research institutions.
Market Cap: $8.6B52W Range: $1.83 – $12.43
Congressional Interest in ImmunityBio, Inc. (IBRX)
2 members of Congress have disclosed 2 trades in ImmunityBio, Inc. (IBRX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
2
Unique Politicians
2
Buys
1
Sells
1
Who in Congress Is Trading IBRX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-03-06 | Daniel Goldman | sell | $1K – $15K |
| 2016-11-30 | Jared Polis | buy | $1K – $15K |